摘要
目的:比较丙戊酸镁与喹硫平治疗青少年双相情感障碍(BD)患者的效果。方法:选取2022年1月至2024年1月该院收治的92例青少年BD患者进行前瞻性研究,按照随机数字表法将其分为对照组与观察组各46例。对照组采用喹硫平治疗,观察组采用丙戊酸镁治疗。比较两组治疗前后疾病严重程度[杨氏躁狂评定量表(YMRS)、临床总体印象-双相情感障碍疾病严重程度量表(CGIBP-s)]评分、生活质量[世界卫生组织生存质量测定量表简表(WHOQOL-BREF)]评分、神经营养因子[血清胶质源性神经营养因子(GDNF)、脑源性神经营养因子(BDNF)]水平,以及不良反应发生率。结果:治疗2个月后,两组YMRS、CGI-BP-s评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗2个月后,两组生理变化、心理领域、社会关系、环境领域、总体状况等WHOQOL-BREF评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗2个月后,两组GDNF、BDNF水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:丙戊酸镁治疗青少年BD患者可提高生活质量和神经营养因子水平,降低疾病严重程度评分,效果优于喹硫平治疗。
Objective:To compare effects of Magnesium valproate and Quetiapine in treatment of adolescent patients with bipolar disorders(BD).Methods:A prospective study was conducted on 92 adolescent BD patients admitted to this hospital from January 2022 to January 2024.According to the random number table method,they were divided into control group and observation group,46 cases in each group.The control group was treated with Quetiapine,while the observation group was treated with Magnesium valproate.The scores of disease severity[Young mania rating scale(YMRS),clinical global impression-bipolar disorder severity scale(CGI-BP-s)],quality of life[World Health Organization Quality of life-BREF(WHOQOL-BREF)],the neurotrophic factors[serum glial cell line-derived neurotrophic factor(GDNF),brain-derived neurotrophic factor(BDNF)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:After 2 months of treatment,the scores of YMRS and CGI-BP-s in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After 2 months of treatment,the WHOQOLBREF scores of physiological changes,psychological field,social relationship,environmental field and overall situation in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After 2 months of treatment,the levels of GDNF and BDNF in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Magnesium valproate in the treatment of the adolescent patients with bipolar disorders can improve the quality of life and the neurotrophic factor levels,and reduce the disease severity scores.Moreover,it is superior to Quetiapine treatment.
作者
王建康
秦文增
王本勇
WANG Jiankang;QIN Wenzeng;WANG Benyong(Department of Psychiatry of Luyi Shijing Hospital,Zhoukou 477200 Henan,China)
出处
《中国民康医学》
2025年第22期72-75,共4页
Medical Journal of Chinese People’s Health
关键词
青少年
双相情感障碍
喹硫平
丙戊酸镁
生活质量
神经营养因子
Adolescent
Bipolar disorder
Quetiapine
Magnesium valproate
Quality of life
Neurotrophic factor
